NCT00351546View on ClinicalTrials.gov

A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

December 31, 2005

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Vildagliptin

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00351546 - A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes | Biotech Hunter | Biotech Hunter